Design of a multi-epitope vaccine candidate against Brucella melitensis
Abstract Brucella is a typical facultative intracellular bacterium that can cause zoonotic infections. For Brucella, it is difficult to eliminate with current medical treatment. Therefore, a multi-epitope vaccine (MEV) should be designed to prevent Brucella infection. For this purpose, we applied th...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2022-06-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-022-14427-z |
| _version_ | 1811343637697527808 |
|---|---|
| author | Min Li Yuejie Zhu Ce Niu Xinru Xie Gulishati Haimiti Wenhong Guo Mingkai Yu Zhiqiang Chen Jianbing Ding Fengbo Zhang |
| author_facet | Min Li Yuejie Zhu Ce Niu Xinru Xie Gulishati Haimiti Wenhong Guo Mingkai Yu Zhiqiang Chen Jianbing Ding Fengbo Zhang |
| author_sort | Min Li |
| collection | DOAJ |
| description | Abstract Brucella is a typical facultative intracellular bacterium that can cause zoonotic infections. For Brucella, it is difficult to eliminate with current medical treatment. Therefore, a multi-epitope vaccine (MEV) should be designed to prevent Brucella infection. For this purpose, we applied the reverse vaccinology approach from Omp10, Omp25, Omp31 and BtpB. Finally, we obtained 13 cytotoxic T lymphocyte (CTL) epitopes, 17 helper T lymphocyte (HTL) epitopes, 9 linear B cell epitopes, and 2 conformational B cell epitopes for further study. To keep the protein folded normally, we linked AAY, GPGPG, and KK to CTL epitopes, HTL epitopes, and B cell epitopes, respectively. The N-terminal of the vaccine peptide is supplemented with appropriate adjuvants to enhance immunogenicity. To evaluate its immunogenicity, stability, safety, and feasibility, a final MEV containing 806 amino acids was constructed by linking linkers and adjuvants. In addition, molecular docking and molecular dynamics simulations were performed to verify the affinity and stability of the MEV-TLR4. Then, codon adaptation and in silico cloning studies were carried out to identify the possible codons for expressing the MEV. In animal experiments, the results demonstrated that the MEV had high immunogenicity. Collectively, this study provided a theoretical basis for the development of a Brucella vaccine. |
| first_indexed | 2024-04-13T19:33:22Z |
| format | Article |
| id | doaj.art-7eaab78289de4633adff900850af4d19 |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-04-13T19:33:22Z |
| publishDate | 2022-06-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-7eaab78289de4633adff900850af4d192022-12-22T02:33:07ZengNature PortfolioScientific Reports2045-23222022-06-0112111810.1038/s41598-022-14427-zDesign of a multi-epitope vaccine candidate against Brucella melitensisMin Li0Yuejie Zhu1Ce Niu2Xinru Xie3Gulishati Haimiti4Wenhong Guo5Mingkai Yu6Zhiqiang Chen7Jianbing Ding8Fengbo Zhang9The First Affiliated Hospital of Xinjiang Medical UniversityDepartment of Reproductive Assistance, Center for Reproductive Medicine, The First Affiliated Hospital of Xinjiang Medical UniversityThe First Affiliated Hospital of Xinjiang Medical UniversityThe First Affiliated Hospital of Xinjiang Medical UniversityThe First Affiliated Hospital of Xinjiang Medical UniversityThe First Affiliated Hospital of Xinjiang Medical UniversityDepartment of Immunology, School of Basic Medical Sciences, Xinjiang Medical UniversityDepartment of Immunology, School of Basic Medical Sciences, Xinjiang Medical UniversityDepartment of Immunology, School of Basic Medical Sciences, Xinjiang Medical UniversityDepartment of Clinical Laboratory, The First Affiliated Hospital of Xinjiang Medical UniversityAbstract Brucella is a typical facultative intracellular bacterium that can cause zoonotic infections. For Brucella, it is difficult to eliminate with current medical treatment. Therefore, a multi-epitope vaccine (MEV) should be designed to prevent Brucella infection. For this purpose, we applied the reverse vaccinology approach from Omp10, Omp25, Omp31 and BtpB. Finally, we obtained 13 cytotoxic T lymphocyte (CTL) epitopes, 17 helper T lymphocyte (HTL) epitopes, 9 linear B cell epitopes, and 2 conformational B cell epitopes for further study. To keep the protein folded normally, we linked AAY, GPGPG, and KK to CTL epitopes, HTL epitopes, and B cell epitopes, respectively. The N-terminal of the vaccine peptide is supplemented with appropriate adjuvants to enhance immunogenicity. To evaluate its immunogenicity, stability, safety, and feasibility, a final MEV containing 806 amino acids was constructed by linking linkers and adjuvants. In addition, molecular docking and molecular dynamics simulations were performed to verify the affinity and stability of the MEV-TLR4. Then, codon adaptation and in silico cloning studies were carried out to identify the possible codons for expressing the MEV. In animal experiments, the results demonstrated that the MEV had high immunogenicity. Collectively, this study provided a theoretical basis for the development of a Brucella vaccine.https://doi.org/10.1038/s41598-022-14427-z |
| spellingShingle | Min Li Yuejie Zhu Ce Niu Xinru Xie Gulishati Haimiti Wenhong Guo Mingkai Yu Zhiqiang Chen Jianbing Ding Fengbo Zhang Design of a multi-epitope vaccine candidate against Brucella melitensis Scientific Reports |
| title | Design of a multi-epitope vaccine candidate against Brucella melitensis |
| title_full | Design of a multi-epitope vaccine candidate against Brucella melitensis |
| title_fullStr | Design of a multi-epitope vaccine candidate against Brucella melitensis |
| title_full_unstemmed | Design of a multi-epitope vaccine candidate against Brucella melitensis |
| title_short | Design of a multi-epitope vaccine candidate against Brucella melitensis |
| title_sort | design of a multi epitope vaccine candidate against brucella melitensis |
| url | https://doi.org/10.1038/s41598-022-14427-z |
| work_keys_str_mv | AT minli designofamultiepitopevaccinecandidateagainstbrucellamelitensis AT yuejiezhu designofamultiepitopevaccinecandidateagainstbrucellamelitensis AT ceniu designofamultiepitopevaccinecandidateagainstbrucellamelitensis AT xinruxie designofamultiepitopevaccinecandidateagainstbrucellamelitensis AT gulishatihaimiti designofamultiepitopevaccinecandidateagainstbrucellamelitensis AT wenhongguo designofamultiepitopevaccinecandidateagainstbrucellamelitensis AT mingkaiyu designofamultiepitopevaccinecandidateagainstbrucellamelitensis AT zhiqiangchen designofamultiepitopevaccinecandidateagainstbrucellamelitensis AT jianbingding designofamultiepitopevaccinecandidateagainstbrucellamelitensis AT fengbozhang designofamultiepitopevaccinecandidateagainstbrucellamelitensis |